Business Wire

Another-1 Immortalizes Street Art and Streetwear with ‘Drip-Lab’ - combining NFTs, PFPs and NFC Technology

20.7.2023 15:00:00 EEST | Business Wire | Press release

Share

Another-1, the web3 luxury fashion platform, today announces the global launch of Drip-Lab – a multi-faceted phygital NFT project in collaboration with Como-based luxury technical fabric mill Olmetex, and renowned graffiti writer and artist Zoow24.

Drip-Lab launches with a mission to define the global intersection of art, graffiti, technology and streetwear, uniting a new and vibrant community of collectors and connoisseurs in the process. By launching a graffiti and street-culture inspired NFT collection, immortalizing Zoow24’s “The Wall” mural as an NFT, as well as linking the artist’s iconic illustrated characters to an NFC-enabled Olmetex fabricated windbreaker jacket, every aspect of the Drip-Lab project combines to ensure that historically ephemeral street art can be recorded, owned and flexed forever.

At the heart of this project are Zoow24’s five instantly recognisable ‘miniature behemoth’ monster character NFTs - REKT, EXTO, KULT, CRYMELON, and ROOT - which represent vices that can cause an artist to lose their way. The NFTs will be available with over 1,700 backgrounds, 183 monster traits, and 5,555 profile pictures (PFPs) variations as the Drip-Lab community grows.

In short, this unique blend of physical and digital (phygital) utility offers ‘Drip-Lab’ holders around the world the chance to flex a range of digital PFPs, physical products and murals, as well as augmented reality experiences that will be revealed with Another-1’s plans for future activations.

The ‘Drip-Lab’ Roadmap
The Pre-mint for ‘Drip-Lab’ is now live in anticipation of the sale on the Another-1 ADO Launchpad, allowing interested community members exclusive access to mint this project by linking their wallet ahead of the public offering.

Next week, on Wednesday, July 26th at 1pm EDT / 5pm UTC, presale for the project opens, and on July 27th at 1pm EDT / 5pm UTC the public sale will go live. An individual PFP will cost $150 USD each and to forge a customized jacket will cost $350 USD. After the drop, added benefits and utilities will be revealed as holders of these PFP project NFTs will benefit from a free airdrop of an NFT that immortalizes ‘The Wall’ art created by Zoow24 in Como. Adding the fashion and streetwear element, a highly anticipated aspect of this project is a limited edition windbreaker jacket that comes equipped with Near Field Communication (NFC) technology.

Designed by Olmetex, a world-renowned Italian mill setting the standard for fashion’s leading technical fabrics, these jackets showcase five captivating thermo-reactive dual-colorways and feature ZOOW24’s monsters on the inside lining for a customized finish.

Apart from making sure its wearer looks good in the streets, ‘The Writer’s Jacket’ will enable its owners’ to take advantage of Another-1’s ‘Flex-To-Earn’ module and get a 25% cash back airdrop in $AN1 tokens once the collection sales have been concluded, and the NFT redeem for the physical Jacket will be available later this year.

Speaking on the project, artist Zoow24 said, “Drip-Lab is a cautionary expose of what vices become when they spiral out of control. When you stop doing the drugs and the drugs do you. Habits are what make us human and how we choose to spend our time defines us as people.” “As a whole, this collaboration with Another-1 and Olmetex has created an opportunity for me to take my art, my characters and my creativity to a whole range of platforms and possibilities.”

Marco Staglianò, CEO of Another-1, added, “Our mission is to push the envelope and radically change the way art is produced and traded. By establishing the Drip-Lab project along with Olmetex and renowned artists such as Zoow24, we are proving that graffiti is a medium that can live on and be appreciated forever. This is a historical crossover of art, fashion, and groundbreaking technology and we’re excited for what’s still to come.”

“Working with a renowned fabric manufacturer like Olmetex, we also have the opportunity to tie physical fashion to this story of street and digital art. This is a first for the world and we’re excited to see how these passionate communities of street art and streetwear collectors will respond.”

Finally, Olmetex Managing Director, Beatrice Breschi had this to say: “Olmetex has decided to make the facade of its textile company available to graffiti artists, because it has always believed in the close union between fashion and art. This approach is a source of inspiration for our customers, which has always been part of our spirit and characteristics: elasticity, flexibility and constant openness to new ideas and challenges that the market offers. With these NFTs and the physical redemption of the waterproof jacket produced with its own fabrics, Olmetex sets itself the goal of making an art project tangible and fashionable.

“We’re excited to see our near-70 year old Mill involved in a web3 project that creates a new and important way to enjoy art and fashion. We have always been future-focused with our fabric innovation, and now we are taking this mindset to a collaboration that takes fashion, art and fabric into the next decade.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bridget van Voorst
bridget@cw8-communications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye